deltatrials
Completed PHASE3 INTERVENTIONAL 1-arm NCT03903562

Immunobridging Study of 9- Valent Human Papillomavirus (9vHPV) Vaccine (V503) in Chinese Females 9 to 45 Years of Age (V503-024)

A Phase 3 Open-Label Clinical Trial to Study the Immunogenicity and Safety of 9- Valent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine (V503) in Chinese Females 9 to 45 Years of Age

Sponsor: Merck Sharp & Dohme LLC

Conditions Papillomavirus Infections
Interventions V503
Updated 18 times since 2019 Last updated: Mar 20, 2025 Started: Apr 27, 2019 Primary completion: Feb 28, 2025 Completion: Feb 28, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Papillomavirus Infections, this trial is completed. The trial is conducted by Merck Sharp & Dohme LLC and has accumulated 18 data snapshots since 2019. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

~May 2019 – ~Jun 2019 · 31 days · monthly snapshot~Jun 2019 – ~Oct 2019 · 4 months · monthly snapshot~Oct 2019 – ~Nov 2019 · 31 days · monthly snapshot~Nov 2019 – ~Apr 2020 · 5 months · monthly snapshot~Apr 2020 – ~Jul 2020 · 3 months · monthly snapshot~Jul 2020 – ~Sep 2020 · 2 months · monthly snapshot~Sep 2020 – ~Oct 2020 · 30 days · monthly snapshot~Oct 2020 – ~Dec 2020 · 2 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Jun 2022 · 16 months · monthly snapshot~Jun 2022 – ~Sep 2022 · 3 months · monthly snapshot~Sep 2022 – ~Feb 2023 · 5 months · monthly snapshot~Feb 2023 – ~Jul 2024 · 17 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Feb 2025 · 5 months · monthly snapshot~Feb 2025 – ~Apr 2025 · 59 days · monthly snapshot~Apr 2025 – present · 17 months · monthly snapshot

Change History

18 versions recorded

  1. Apr 2025 — Present [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  2. Feb 2025 — Apr 2025 [monthly]

    Active Not Recruiting PHASE3

  3. Sep 2024 — Feb 2025 [monthly]

    Active Not Recruiting PHASE3

  4. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE3

  5. Feb 2023 — Jul 2024 [monthly]

    Active Not Recruiting PHASE3

▶ Show 13 earlier versions

  1. Sep 2022 — Feb 2023 [monthly]

    Active Not Recruiting PHASE3

  2. Jun 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE3

  3. Feb 2021 — Jun 2022 [monthly]

    Active Not Recruiting PHASE3

  4. Jan 2021 — Feb 2021 [monthly]

    Active Not Recruiting PHASE3

  5. Dec 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE3

  6. Oct 2020 — Dec 2020 [monthly]

    Active Not Recruiting PHASE3

  7. Sep 2020 — Oct 2020 [monthly]

    Active Not Recruiting PHASE3

  8. Jul 2020 — Sep 2020 [monthly]

    Active Not Recruiting PHASE3

  9. Apr 2020 — Jul 2020 [monthly]

    Active Not Recruiting PHASE3

  10. Nov 2019 — Apr 2020 [monthly]

    Active Not Recruiting PHASE3

  11. Oct 2019 — Nov 2019 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  12. Jun 2019 — Oct 2019 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  13. May 2019 — Jun 2019 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Apr 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Merck Sharp & Dohme LLC
Data source: Merck Sharp & Dohme LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations